402 related articles for article (PubMed ID: 37353287)
1. Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia.
Pang Y; Holtzman NG
Best Pract Res Clin Haematol; 2023 Jun; 36(2):101475. PubMed ID: 37353287
[TBL] [Abstract][Full Text] [Related]
2. The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation.
Maurer K; Soiffer RJ
Expert Rev Hematol; 2023; 16(12):943-962. PubMed ID: 37906445
[TBL] [Abstract][Full Text] [Related]
3. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210
[TBL] [Abstract][Full Text] [Related]
4. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
5. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
Chang YJ; Zhao XY; Huang XJ
Front Immunol; 2018; 9():3041. PubMed ID: 30619371
[TBL] [Abstract][Full Text] [Related]
6. The graft-versus-leukemia effect of prophylactic donor lymphocyte infusions after allogeneic stem cell transplantation is equally effective in relapse prevention but safer compared to spontaneous graft-versus-host disease.
Stadler M; Hambach L; Dammann E; Diedrich H; Kamal H; Hamwi I; Schultze-Florey C; Varvenne M; Ehrlich S; Buchholz S; Koenecke C; Beutel G; Weissinger EM; Krauter J; Eder M; Hertenstein B; Ganser A
Ann Hematol; 2023 Sep; 102(9):2529-2542. PubMed ID: 37490114
[TBL] [Abstract][Full Text] [Related]
7. The FcgammaRIIa-polymorphic site as a potential target for acute graft-versus-host disease in allogeneic stem cell transplantation.
van der Straaten HM; Fijnheer R; Nieuwenhuis HK; van de Winkel JG; Verdonck LF
Biol Blood Marrow Transplant; 2005 Mar; 11(3):206-12. PubMed ID: 15744239
[TBL] [Abstract][Full Text] [Related]
8. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
[TBL] [Abstract][Full Text] [Related]
9. New developments in allotransplant immunology.
Barrett AJ; Rezvani K; Solomon S; Dickinson AM; Wang XN; Stark G; Cullup H; Jarvis M; Middleton PG; Chao N
Hematology Am Soc Hematol Educ Program; 2003; ():350-71. PubMed ID: 14633790
[TBL] [Abstract][Full Text] [Related]
10. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
Theurich S; Fischmann H; Shimabukuro-Vornhagen A; Chemnitz JM; Holtick U; Scheid C; Skoetz N; von Bergwelt-Baildon M
Cochrane Database Syst Rev; 2012 Sep; (9):CD009159. PubMed ID: 22972135
[TBL] [Abstract][Full Text] [Related]
11. Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab.
Matthews K; Lim Z; Pearce L; Pagliuca A; Alejandro Madrigal J; Mufti GJ; Barber LD
Br J Haematol; 2010 Jun; 149(6):879-89. PubMed ID: 20346011
[TBL] [Abstract][Full Text] [Related]
12. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
13. The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells.
Zhang J; Chen HM; Ma G; Zhou Z; Raulet D; Rivera AL; Chen SH; Pan PY
Leukemia; 2019 Aug; 33(8):2078-2089. PubMed ID: 30737483
[TBL] [Abstract][Full Text] [Related]
14. Randomised trials of Graft versus Host Disease prophylaxis in haemopoietic stem cell transplantation.
Potter V; Moore J
Rev Recent Clin Trials; 2008 May; 3(2):130-8. PubMed ID: 18474024
[TBL] [Abstract][Full Text] [Related]
15. Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
Davies JK; Hassan S; Sarker SJ; Besley C; Oakervee H; Smith M; Taussig D; Gribben JG; Cavenagh JD
Br J Haematol; 2018 Feb; 180(3):346-355. PubMed ID: 29076145
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
17. Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT.
Mammadli M; Huang W; Harris R; Sultana A; Cheng Y; Tong W; Pu J; Gentile T; Dsouza S; Yang Q; Bah A; August A; Karimi M
Front Immunol; 2020; 11():593863. PubMed ID: 33324410
[TBL] [Abstract][Full Text] [Related]
18. Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
Li JM; Giver CR; Lu Y; Hossain MS; Akhtari M; Waller EK
Immunotherapy; 2009 Jul; 1(4):599-621. PubMed ID: 20191089
[TBL] [Abstract][Full Text] [Related]
19. Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation.
Tang Y; Zhou Z; Yan H; You Y
Front Immunol; 2022; 13():810284. PubMed ID: 35185899
[TBL] [Abstract][Full Text] [Related]
20. The impact of regulatory T cells on the graft-versus-leukemia effect.
Pacini CP; Soares MVD; Lacerda JF
Front Immunol; 2024; 15():1339318. PubMed ID: 38711496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]